1 citations
,
April 2023 in “Veterinary medicine and science” The main prostate diseases in dogs are benign growth, infections, and cancer, with various treatments ranging from drugs to surgery, but cancer treatments have limited success.
1 citations
,
January 2019 in “PubMed” Baldness score can't be used to predict prostate size.
1 citations
,
October 2018 in “Journal of The European Academy of Dermatology and Venereology” Vertex baldness has higher DHT levels than frontal baldness, but testosterone and PSA levels are similar.
1 citations
,
December 2017 in “The Journal of Urology” Low-dose finasteride and dutasteride reduce PSA levels by 27.8% in men with male androgenetic alopecia.
March 2024 in “PLoS medicine” Physical activity, height, and smoking affect prostate cancer risk.
April 2022 in “Authorea (Authorea)” CT scans can find serious prostate cancer even when PSA levels are low.
August 2020 in “Cornea” Men with benign prostate hyperplasia have more meibomian gland loss and tear film problems.
September 2011 Finasteride's effects on prostate cancer are not clear from this text.
June 2011 in “Oncology times” New treatments are making advanced prostate cancer management more complex but also more hopeful.
March 2011 in “European Urology Supplements” The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.
October 2010 in “The Journal of urology/The journal of urology” Male pattern baldness may be linked to prostate cancer risk.
September 2010 in “European Urology Supplements” Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.
September 2010 in “European Urology Supplements” The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.
September 2010 in “European Urology Supplements” Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.
September 2010 in “European Urology Supplements” Serum triglyceride levels are not linked to prostate cancer risk.
September 2009 in “European Urology Supplements” Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.
April 2009 in “The Journal of Urology” Shorter PSADT after prostate surgery is linked to higher risk of death.
October 2008 in “The Journal of Urology” Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.
March 2007 in “BJUI” Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
February 2007 in “Lancet Oncology” Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.
April 2005 in “The Journal of urology/The journal of urology” Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.
January 2019 in “Central European Journal of Urology”
April 2012 in “The Journal of Urology” Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.
March 2011 in “European Urology Supplements” Gene variation affects prostate issues and hair loss.
January 2008 in “The Year book of endocrinology” Gene variant linked to prostate cancer, hormone levels, and hair loss.
237 citations
,
December 2001 in “Urology” Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.
148 citations
,
May 2009 in “Molecular Pharmaceutics” Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.
147 citations
,
July 2011 in “New England journal of medicine/The New England journal of medicine” 5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
116 citations
,
May 1992 in “The American Journal of Medicine” Flutamide rarely causes liver toxicity in prostate cancer patients.
108 citations
,
April 2008 in “The Journal of urology/The journal of urology” Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.